利妥昔单抗治疗传统免疫抑制治疗效果不佳的 Vogt-Koyanagi-Harada 病的疗效。
Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment.
机构信息
Ocular Immunology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.
Rheumatology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.
出版信息
Ocul Immunol Inflamm. 2022 Aug;30(6):1303-1308. doi: 10.1080/09273948.2021.1880604. Epub 2021 Apr 1.
PURPOSE
To evaluate the efficacy of Rituximab (RTX) therapy in patients affected by Vogt-Koyanagi-Harada (VKH) disease poorly controlled by traditional immunosuppressive treatment.
METHODS
Retrospective case series of recurrent VKH uveitis treated with intravenous RTX between January 2019 and November 2020. All patients were treated with intravenous RTX and underwent complete ophthalmic examination, best-corrected visual acuity (BCVA), fundus photography, subfoveal choroidal thickness (SFCT) measurement on enhanced depth imaging optical-coherence tomography (EDI-OCT), fluorescein, and indocyanine green angiography.
RESULTS
Five patients were included. All patients received at least 3 RTX infusions. Mean BCVA improved from 20/32 Snellen equivalent at baseline before RTX treatment to 20/28 Snellen equivalent ( = .008). Mean SFCT on EDI-OCT showed a reduction from 564.4 µm(SD = 176.2) to 280.0 µm(SD = 140.4) ( = .015). Follow-up ranged from 12 to 21 months, with a mean of 18.2 ± 3.7 months.
CONCLUSIONS
In these case series, RTX was effective in VHK disease poorly controlled by traditional immunosuppressive treatment.
目的
评估利妥昔单抗（RTX）治疗传统免疫抑制治疗效果不佳的 Vogt-小柳原田（VKH）病患者的疗效。
方法
回顾性病例系列研究，纳入 2019 年 1 月至 2020 年 11 月期间接受静脉注射 RTX 治疗的复发性 VKH 葡萄膜炎患者。所有患者均接受静脉注射 RTX 治疗，并进行全面眼科检查、最佳矫正视力（BCVA）、眼底照相、增强深度成像光学相干断层扫描（EDI-OCT）下的中心凹下脉络膜厚度（SFCT）测量、荧光素和吲哚青绿血管造影。
结果
共纳入 5 例患者。所有患者均至少接受了 3 次 RTX 输注。平均 BCVA 从 RTX 治疗前基线时的 20/32 视力表等价物提高至 20/28 视力表等价物（ = 0.008）。EDI-OCT 上的平均 SFCT 从 564.4 µm（SD = 176.2）下降到 280.0 µm（SD = 140.4）（ = 0.015）。随访时间为 12 至 21 个月，平均为 18.2 ± 3.7 个月。
结论
在这些病例系列研究中，RTX 对传统免疫抑制治疗效果不佳的 VKH 病有效。
Zotero 插件